Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 240Lymphoma 178Lymphoma, Large B-Cell, Diffuse 172Precursor Cell Lymphoblastic Leukemia-Lymphoma 87Lymphoma, Follicular 79Lymphoma, Non-Hodgkin 73Burkitt Lymphoma 66Multiple Myeloma 64Leukemia 57Hodgkin Disease 45Lymphoma, Mantle-Cell 41Neoplasms 34Lymphoma, T-Cell, Peripheral 31Lymphoma, B-Cell 30Lymphoma, B-Cell, Marginal Zone 28Lymphoma, Large-Cell, Anaplastic 26Neoplasm Metastasis 25Lymphoma, Large-Cell, Immunoblastic 24Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Neoplasms, Plasma Cell 21Recurrence 20Immunoblastic Lymphadenopathy 15Dendritic Cell Sarcoma, Interdigitating 15Lymphoma, T-Cell 14Leukemia, Biphenotypic, Acute 10Waldenstrom Macroglobulinemia 9Blast Crisis 9Primary Myelofibrosis 8Myelodysplastic Syndromes 8

Interventions

prednylidene 1deltacortene 1cabazitaxel 1XRP6258 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone-Resistant Prostate Cancer × Prednisone × Clear all
NCT02844582 2021-01-25

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

Phase 2 Terminated
2 enrolled 5 charts
Genitourinary

Hormone-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡